Dataset Information

Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study.

ABSTRACT:

Aim

IL-18 is hypothesized to destabilise atherosclerotic plaques, leading to thrombotic events and epidemiologic studies suggest that IL-18 may increase risk of CHD or CVD. We examined prospective associations between levels of serum IL-18 and new CHD and stroke events in older men and women from a general population.

Methods

A case-control study was nested within a prospective cohort of men and women aged 60-79 years recruited from general practices in 25 British towns in 1998-2000 and followed-up for 7.5 years for fatal and non-fatal MI and stroke. Baseline IL-18 was measured in stored serum samples of incident cases of MI (n=364) or stroke (n=300) and two controls per case.

Results

Geometric mean IL-18 levels were higher among the 364 MI cases than the 706 controls; 417.84 pg/mL (IQR 316.25, 537.44) compared to 386.90 pg/mL (IQR 296.54, 482.33), p(difference)=0.002. IL-18 was positively associated with adverse lipid and inflammatory profiles. Men and women in the top third of baseline IL-18 levels had an age and sex-adjusted odds ratio (OR) for MI of 1.31 (95%CI 0.92, 1.85) compared with those in the lowest third; this attenuated to 1.05 (95%CI 0.72, 1.53) after additional adjustment for established vascular and inflammatory risk factors. Each doubling of IL-18 level was associated with an increased OR for MI 1.34 (95%CI 1.04, 1.72), which was attenuated on adjustment for established vascular and inflammatory risk factors; 1.09 (95%CI 0.83, 1.44). Geometric mean IL-18 levels did not differ between stroke cases and controls. The OR for stroke associated with the highest compared to the lowest tertile of IL-18 was 1.24 (95%CI 0.84, 1.84). Results for MI and stroke did not differ by presence of pre-existing CVD, gender or age.

Conclusions

Circulating IL-18 levels were strongly associated with a range of established and novel risk factors but were not independently associated with risk of MI or stroke in our study.

SUBMITTER: Jefferis BJ

PROVIDER: S-EPMC3561593 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study.

Jefferis Barbara J BJ Whincup Peter H PH Welsh Paul P Wannamethee S Goya SG Rumley Ann A Ebrahim Shah S Lawlor Debbie A DA Lowe Gordon D O GD

Cytokine 20121201 2

<h4>Aim</h4>IL-18 is hypothesized to destabilise atherosclerotic plaques, leading to thrombotic events and epidemiologic studies suggest that IL-18 may increase risk of CHD or CVD. We examined prospective associations between levels of serum IL-18 and new CHD and stroke events in older men and women from a general population.<h4>Methods</h4>A case-control study was nested within a prospective cohort of men and women aged 60-79 years recruited from general practices in 25 British towns in 1998-20 ...[more]

PMID: 23207179

Similar Datasets

Project description:IntroductionField tests to estimate maximal oxygen consumption (VO2max) are an alternative to traditional exercise testing methods. Published field tests and their accompanying estimation equations account for up to 80% of the variance in VO2max with an error rate of ~4.5 ml.kg-1.min-1. These tests are limited to very specific age-range populations. The purpose of this study was to create and validate a series of easily administered walking and stepping field equations to predict VO2max across a range of healthy 18-79-year-old adults.MethodsOne-hundred-fifty-seven adults completed a graded maximal exercise test to assess VO2max. Five separate walking and three separate stepping tests of varying durations, number of stages, and intensities were completed. VO2max estimation equations were created using hierarchal multiple regression. Covariates including age, sex, body mass, resting heart rate, distance walked, gait speed, stepping cadence, and recovery heart rate were entered into each model using a stepwise approach. Each full model created had the same base model consisting of age, sex, and body mass. Validity of each model was assessed using a Jackknife cross-validation analysis, and percent bias and root mean square error (RMSE) were calculated.ResultsBase models accounted for ~72% of the total variance of VO2max. Full model variance ranged from ~79-83% and bias was minimal (<±1.0%) across models. RMSE for all models were approximately 4.5 ml.kg-1.min-1. Stepping tests performed better than walking tests by explaining ~2.5% more of the variance and displayed smaller RMSE.ConclusionAll eight models accounted for a large percentage of VO2max variance (~81%) with a RMSE of ~4.5 ml.kg-1.min-1. The variance and level of error of models examined highlight good group mean prediction with greater error expected at the individual level. All the models perform similarly across a broad age range, highlighting flexibility in application of these tests to a more general population.

Project description:Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine containing half of the registered adult haemagglutinin (HA) antigen content, administered as a two-dose schedule at intervals of 21?days or 6?months in both young and elderly adults.In this open-label randomized trial, healthy adults aged 18-60?years (N?=?163) and >60?years (N?=?143) received AS03A-adjuvanted A/California/7/2009 H1N1 vaccine containing 1.9??g HA on Day 0. A second dose was given on Day 21 (n?=?177) or Day 182 (n?=?106). Haemagglutination-inhibition (HI) antibody responses were analyzed on Days 0, 21, 42, 182, 364 and additionally on Day 203 for subjects vaccinated on Day 182. Solicited and unsolicited adverse events were recorded.The HI antibody response in both age strata 21?days after the first dose met and exceeded all regulatory acceptance criteria although the results suggested a lower response in the older age stratum (geometric mean titres [GMTs] for HI antibodies of 420.5 for subjects aged 18-60?years and 174.4 for those >60?years). A second dose of AS03A adjuvanted A/H1N1/2009 vaccine induced a further increase in antibody titres and the response was similar whether the second dose was administered at 21?days (GMTs of 771.8 for 18-60?years and 400.9 for >60?years) or 6?months (GMTs of 708.3 for 18-60?years and 512.1 for >60?years) following the first dose. Seroprotection rates remained high at 6?months after one dose or two doses while at 12?months rates tended to be higher for the 6?month interval schedule (93.3% for 18-60?years and 80.4% for >60?years) than the 21?day schedule (82.3% for 18-60?years and 50.0% for >60?years). Reactogenicity/safety profiles were similar for both schedules, there was no evidence of an increase in reactogenicity following the second dose.The results indicate that flexibility in the dosing interval for AS03A adjuvanted vaccine may be possible. Such flexibility could help to reduce the logistic stress on delivery of pandemic vaccination programmes.ClinicalTrials.gov, NCT00975884.

Project description:BackgroundAge-related chronic low-grade inflammation (inflammaging) is one of the proposed mechanisms behind sarcopenia. However, findings regarding inflammatory markers in sarcopenic older adults are conflicting. This study aimed to determine the association between inflammatory markers, prevalent as well as incident sarcopenia, sarcopenia-defining parameters, quality of life (QoL), and physical activity in middle-aged and older men.MethodsMen aged 40-79 years (mean 59.66 ± 11.00y) were recruited from population registers in eight European centres for participation in the European Male Aging study (EMAS). Subjects were assessed at baseline (2003-2005) and again after a median follow-up of 4.29 years. In 2577 participants, associations between baseline inflammatory markers [high-sensitive C-reactive protein (hs-CRP), white blood cell count (WBC), albumin] and baseline physical activity (PASE) and QoL (SF-36) were analysed. In the Leuven and Manchester cohort (n = 447), data were available on muscle mass (whole-body dual X-ray absorptiometry) and strength. In this subgroup, cross-sectional associations between baseline inflammatory markers and sarcopenia-defining parameters (handgrip strength, chair stand test, appendicular lean mass, and gait speed) and prevalent sarcopenia were examined. In a further subgroup (n = 277), associations with knee extensor strength were explored. Longitudinally, predictive value of baseline inflammation on functional decline, physical activity, QoL, and incident sarcopenia was examined. Subgroup analyses were performed in subgroups with chronic inflammation and stratified by age. Linear and logistic regressions were used, adjusted for age, body mass index, centre, and smoking.ResultsAt baseline, hs-CRP and WBC were negatively associated with PASE score (hs-CRP: β = -7.920, P < 0.001; and WBC: β = -4.552, P < 0.001) and the physical component score of SF-36 (hs-CRP: β = -1.025, P < 0.001; and WBC: β = -0.364, P < 0.001). Baseline WBC levels were negatively associated with gait speed (β = -0.013; P = 0.025), quadriceps isometric 90° (β = -5.983; P = 0.035) and isokinetic 60°/s peak torque/body weight (β = -5.532; P = 0.027). The prevalence of sarcopenia at baseline was 18.1% (n = 81). Of those without sarcopenia at baseline, 64 (18.6%) satisfied criteria for sarcopenia at follow-up. There were no significant associations between baseline inflammatory markers and either prevalent or incident sarcopenia, or change in level of sarcopenia-defining parameters between baseline and follow-up.ConclusionsIn middle-aged and older men, hs-CRP and WBC were negatively associated with QoL and PASE scores, while WBC was negatively associated with gait speed and knee strength. Associations with hs-CRP remained significant in all ages, whereas WBC levels were only associated with PASE, gait speed and knee strength in older adults (60-79 years). Baseline inflammatory markers (hs-CRP, WBC and albumin) did not predict functional decline, decline in physical activity, decreased QoL or incident sarcopenia.

Dataset Information

Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study.

Aim

Methods

Results

Conclusions

Publications

Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets